ストックスクリーナーアプリを入手
2.3305
2.11%
-0.1195
前日終値:
$2.45
開ける：
$2.41
24時間の取引高:
12,969
Relative Volume:
0.14
時価総額：
$39.37M
収益：
-
当期純損益:
$-24.05M
株価収益率:
-1.084
EPS:
-2.15
ネットキャッシュフロー:
$-17.78M
1週間 パフォーマンス:
+6.82%
1か月 パフォーマンス:
-19.52%
6か月 パフォーマンス:
-28.84%
1年 パフォーマンス:
-48.09%
1日の値動き範囲:
$2.32
$2.4499
1週間の範囲:
$2.23
$2.45
52週間の値動き範囲:
$2.0278
$6.48
Envveno Medical Corporation Stock (NVNO) Company Profile
NVNO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
2.355 | 39.37M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
129.19 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.66 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
337.71 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
81.46 | 105.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Envveno Medical Corporation (NVNO) 最新ニュース
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment | NVNO Stock News - GuruFocus
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment - Eagle-Tribune
Press Release Distribution & PR Platform - ACCESS Newswire
Live Today: enVVeno Medical Unveils Game-Changing Venous Valve Technology - Stock Titan
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer - ACCESS Newswire
Financial Analysis: ClearPoint Neuro (NASDAQ:CLPT) vs. enVVeno Medical (NASDAQ:NVNO) - Defense World
NVNO stock touches 52-week low at $2.45 amid market challenges - Investing.com
We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely - simplywall.st
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium - Weatherford Democrat
Virtu Financial LLC Buys Shares of 28,533 enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
VenoValve trial shows sustained patient benefits at 24 months - MSN
Sanctuary Advisors LLC Makes New Investment in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - BioSpace
enVVeno Medical (NVNO) to Release Earnings on Thursday - MarketBeat
enVVeno Medical expects capital to fund company through several milestones - TipRanks
enVVeno Medical Files For Mixed Shelf Of Up To $100 MillionSEC Filing - TradingView
enVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last year - TipRanks
NVNOEnvveno Medical Corporation Latest Stock News & Market Updates - StockTitan
EnVVeno Medical Reports Fourth Quarter and Year-End 2024 Financi - News Channel Nebraska
Can enVVeno's $43M Cash Runway Carry VenoValve Through FDA Approval? Clinical Data Shows 78% Success Rate - Stock Titan
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing - ACCESS Newswire
enVVeno Medical (NVNO) Projected to Post Quarterly Earnings on Thursday - Defense World
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
enVVeno Medical (NASDAQ:NVNO) Shares Up 6.4%Here's Why - MarketBeat
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference - ACCESS Newswire
One-year data from VenoValve US pivotal trial highlighting impact on patients’ QoL presented at AVF 2025 - Venous News
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum - BioSpace
enVVeno Announces One Year Data from VenoValve U.S. Pivotal Trial - MPO-mag
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Milton Daily Standard
Can These 5 Growth Drivers Make enVVeno Medical the Next Big Thing in Venous Disease Treatment? - StockTitan
enVVeno Medical presents one-year data from VenoValve trial - TipRanks
Revolutionary Vein Treatment Shows Lasting Benefits: Will FDA Grant First-Ever Approval for Deep CVI? - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga India
VenoValve trial shows sustained patient benefits at 24 months By Investing.com - Investing.com South Africa
enVVeno Medical presents two-year follow-up data from VenoValve trial - TipRanks
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting - ACCESS Newswire
VenoValve Clinical Trial Hits Home Run: 100% Patency Rate Stuns Medical Community - Stock Titan
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference - ACCESS Newswire
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity - ACCESS Newswire
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R) - ACCESS Newswire
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 - ACCESS Newswire
Westside Investment Management Inc. Acquires 116,650 Shares of enVVeno Medical Corporation (NASDAQ:NVNO) - MarketBeat
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering - ACCESS Newswire
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - ACCESS Newswire
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth - Yahoo Finance
enVVeno Medical Corporation (NASDAQ:NVNO) Shares Bought by Geode Capital Management LLC - Defense World
Envveno Medical Corporation (NVNO) 財務データ
収益
当期純利益
現金流量
EPS
0.81%
1.34%
大文字化:
|
ボリューム (24 時間):